Safety and Efficacy of BIND-014, a Docetaxel Nanoparticle Targeting Prostate-Specific Membrane Antigen for Patients With Metastatic Castration-Resistant Prostate Cancer: A Phase 2 Clinical Trial

• Published in: JAMA oncology Vol. 4; no. 10; p. 1344
• Main Authors: Autio, Karen A, Dreicer, Robert, Anderson, Justine, Garcia, Jorge A, Alva, Ajjai, Hart, Lowell L, Milowsky, Matthew I, Posadas, Edwin M, Ryan, Charles J, Graf, Ryon P, Dittamore, Ryan, Schreiber, Nicole A, Summa, Jason M, Youssoufian, Hagop, Morris, Michael J, Scher, Howard I
• Format: Journal Article
• Language: English
• Published: United States 01.10.2018
• Subjects: Aged; Aged, 80 and over; Antineoplastic Agents - adverse effects; Antineoplastic Agents - therapeutic use; Diarrhea - chemically induced; Disease-Free Survival; Docetaxel - adverse effects; Docetaxel - therapeutic use; Fatigue - chemically induced; Humans; Male; Middle Aged; Nanoparticles - adverse effects; Nanoparticles - therapeutic use; Nausea - chemically induced; Neoplasm Metastasis; Prostate-Specific Antigen - antagonists & inhibitors; Prostate-Specific Antigen - metabolism; Prostatic Neoplasms, Castration-Resistant - drug therapy; Prostatic Neoplasms, Castration-Resistant - metabolism; Prostatic Neoplasms, Castration-Resistant - pathology; Treatment Outcome

Preferential delivery of docetaxel to tumors by prostate-specific membrane antigen (PSMA)-targeted nanoparticles is clinically effective, and the selective reduction of PSMA-positive circulating tumor cells (CTCs) after treatment has implications for patient selection and disease monitoring. To dete...